Flipper, the reason this appears contradictory is because the filings are describing two entirely separate things. Once those are separated, the structure becomes straightforward.
The Sawston facility already has licensed, operational Grade B, Grade C and Grade D cleanrooms. That is not conjecture. It is documented in Advent’s MHRA Manufacturing and Import Authorisations and in the UK Cell and Gene Therapy Catapult report, which lists Advent with two Grade B suites, three Grade C rooms and two Grade D rooms. MHRA only licenses rooms that already exist, have been inspected and have passed environmental and process validation. Those rooms have been in active use for years for ATMP manufacturing, including DCVax production during the Phase 3 extension period, Specials supply and validation runs.
The section of the 10K you quoted is not talking about those existing rooms. It is discussing future expansion. That section describes a planned buildout called the simplified Grade C lab. This is a new construction project inside unused shell space that Advent intends to complete so the Eden and Flaskworks systems can be deployed at commercial scale. The filing states that this simplified C-lab will sit next to an existing Grade B lab and will borrow its infrastructure, which is how it can be built more quickly and at lower cost than the two larger Grade C labs originally designed. The simplified C-lab is not the same thing as the existing Grade C cleanrooms and it does not replace them. It is an additional module meant to expand capacity.
The existing Grade C rooms are already part of the current manufacturing layout. They support controlled upstream operations that do not require Grade B sterility, such as preparatory steps that feed into the Grade B suites where open manipulations occur. These rooms are licensed and actively used. They are not placeholders and they are not tied to the future C-lab project.
SOW 8 is also being misread. Statement of Work 8 covers process transfer and validation for DCVax Direct. It includes operator qualification, aseptic simulations, three consecutive full-scale PQQ batches, sterility and mycoplasma testing, assay validation and fill finish validation. None of this work can be done in a room that is still being built. It must occur in functioning, licensed GMP cleanrooms with validated air handling and active quality systems. The fact that NWBO accrued and completed this milestone confirms that the required rooms were already operational.
Eden can run in the existing Grade C rooms because Eden is a closed system. Closed systems do not require a Grade B background under MHRA rules. Grade C is acceptable for closed-system cell processing. The simplified C-lab is not being built because Eden cannot run in the existing cleanrooms. It is being built because NWBO needs more Eden capacity for commercial scale, and the simplified design allows that expansion to proceed faster and at lower cost than constructing two full Grade C labs at once.
The simplified C-lab is an extra capacity module; the existing Grade C cleanrooms are part of the current DCVax manufacturing layout. They serve different purposes, appear in different sections of the filings and exist on different timelines. Once those two categories are separated, every line in the filing becomes consistent.
Bullish
Market Data 
Markets 
